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1. Introduction 
The natriuretic peptides are a group of endogenous, structurally related hormones with 
natriuretic, diuretic and peripheral vasodilatory actions. (Hunt, 1997; Yandle, 1986; Yandle, 
1993) They serve an important regulatory role in response to acute increases in ventricular 
wall stress. A large number of cardiac conditions may cause an elevation of plasma levels of 
natriuretic peptides. Clinically, natriuretic peptides are of value in ruling out heart failure in 
patients presenting acutely to the emergency department with dyspnoea. (Maisel et al., 
2002). Natriuretic peptides could also be useful in evaluating the severity and prognosis of 
patients with aortic stenosis (AS). Severe AS causes an increase in afterload and end-systolic 
left ventricular (LV) wall stress that, over time, leads to concentric myocardial hypertrophy. 
(Wachtell, 2008) This anatomical change of the LV is characterized at the molecular level by 
the re-expression of fetal isogenes, including increased gene expression of natriuretic 
peptides in the ventricular cardiomyocytes. (Sadoshima, 1992; Cameron, 1996) 
This chapter reviews the existing data on natriuretic peptide measurement in AS, to 
summarize how these biomarkers can be utilized in clinical practice, and to explore their 
therapeutic implication concerning the optimal timing of aortic valve replacement in the 
setting of severe AS. 
2. Management of severe Aortic Stenosis 
2.1 Difficulty in determining the timing of valvular surgery 
AS is a slowly progressive disease and current guidelines recommend that surgery is 
delayed until symptoms develop or LV function decreases. (Bonow et al., 2006) Initial 
symptoms experienced by patients with AS are often subtle and insidious and can be 
difficult to evaluate clinically. However, once significant symptoms develop, there is a 
dramatic change in patients’ outlook with a reported average survival on medical therapy of 
less than 3 years. (Ross Jr, 1968; Frank, 1973) The risk of rapid clinical deterioration and 
poorer prognosis after symptom onset in some AS patients emphasizes the importance of 
early and accurate detection of AS related symptoms and timely referral for valvular 
surgery to avoid adverse cardiovascular outcomes in these patients. 
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Echocardiography is currently the gold standard for the non-invasive assessment of AS. The 
most widely used echocardiographic measures of AS severity in clinical practice are peak 
aortic velocity and aortic valve area determined by the continuity equation. (Otto, 1998) 
However, according to the current American College of Cardiology/American Heart 
Association guidelines, there is no single clinical, haemodynamic, or echocardiographic 
measure that has been adopted as a class I recommendation for valve replacement in the 
absence of symptoms in patients with isolated AS. (Bonow et al., 2006) This is because of the 
wide overlaps in haemodynamic and echocardiographic measures of severity between the 
symptomatic and asymptomatic patients, consistent with the known heterogeneous 
response to the pressure load of AS. (Otto, 2000) 
There is also the problem of evaluating symptoms. Patients may not realize gradual onset of 
symptoms is due to disease progression. Also some patients may be unable to exercise 
because of non-cardiac comorbidities, or do not develop the classic symptoms of AS. This 
makes the determination of the optimal timing of aortic valve replacement (AVR) more 
challenging.  
There is reluctance to perform surgery earlier than necessary because of a mortality rate for 
aortic valve surgery of approximately 3% to 5%, even in patients younger than 70 years, 
(Edwards et al., 2001) and prosthetic valve-related long-term morbidity. Conversely, 
patients who become symptomatic are at significant risk of developing adverse cardiac 
events while waiting for surgery, and peri-operative risk increases significantly with the 
severity of symptoms. (Rosenhek et al., 2002) These factors contribute to the controversy on 
the optimal timing of AVR in asymptomatic severe AS, because the risk of potential adverse 
cardiac complications from AS must be weighed against the risk of surgery in truly 
asymptomatic patients.  
A non-invasive marker of early cardiac decompensation could be useful to risk stratify 
asymptomatic AS patients into those likely to derive benefit from surgery before the 
development of symptoms or irreversible LV impairment, from those who have a low risk 
of adverse events during follow-up.  
2.2 Non-invasive biomarkers 
Cardiac biomarkers are one solution to this dilemma. In recent years, biomarkers have 
become important tools for diagnosis, risk stratification and therapeutic decision making in 
cardiovascular diseases. To serve as markers of cardiac function, the biomarkers need to 
predict clinical and echocardiographic progression of disease. Echocardiographic 
assessment of AS requires trained and experienced sonographers with meticulous attention 
to the technical details of imaging and Doppler flow recording and accurate interpretation 
of findings. In contrast the introduction of fully automated assays with proven excellent test 
precision means that measurement of plasma levels of biomarkers is simple, reliable, not 
operator-dependent, relatively inexpensive, and reproducible.  
Several biomarkers have been studied for this purpose. They include atrial natriuretic peptide 
(also known A-type natriuretic peptide, or ANP), brain natriuretic peptide (also known as B-
type natriuretic peptide, or BNP), N-terminal BNP (the amino terminal part of BNP, or NT-
BNP), N-terminal-proBNP (the amino terminal part of the BNP prohormone, or NT-proBNP), 
urodilatin, cardiotrophin-1, tumour necrosis factor-a (TNF-a) and TNF receptors 1 and 2. Of 
these the natriuretic peptides BNP and NT-proBNP predict adverse outcomes across a broad 
range of cardiac diseases in a great number of different clinical settings.  
www.intechopen.com
Natriuretic Peptides in Severe Aortic Stenosis –  
Role in Predicting Outcomes and Assessment for Early Aortic Valve Replacement 
 
205 
2.3 Natriuretic peptides 
BNP was initially identified and described in 1988 after isolation from porcine brain. It was 
later recognised that BNP is predominately synthesized and secreted from the LV in 
response to increased ventricular wall stress. In the setting of volume and pressure 
overload, the increased wall stress initiates synthesis of the prehormone, pre-proBNP which 
is cleaved first to pro-BNP, then to the biologically active BNP and the inactive NT-proBNP 
fragments upon release into the circulation (Figure 1 and 2).  
 
 
Fig. 1. Synthesis and secretion of B-type natriuretic peptide. (adapted from Bettencourt et al., 
2005) 
In contrast to BNP, ANP which is stored in granules within the atria and is released 
immediately after atrial stretch. (Yasue et al., 1994) Only small amounts of BNP are stored in 
granules. Rapid gene expression with de novo synthesis seems to be the underlying 
mechanism for the regulation of BNP secretion. (Yoshimura et al., 1993) However, the exact 
signalling pathways of natriuretic peptide secretion remain poorly defined. During the 
development of LV hypertrophy, gradual disappearance of natriuretic peptide clearance 
receptor mRNA had been found in the rat heart (Brown et al., 1993) and down-regulation of 
membrane-bound natriuretic peptide clearance receptor may, therefore, be a contributing 
factor to increased plasma natriuretic peptide levels. 
As shown in Figure 3, in patients with normal LV systolic function and normal LA pressure, 
BNP and NT-proBNP levels correlate more significantly with LV mass index than ANP 
irrespective of aetiology. (Qi et al., 2001) 
Because of differences in the excretion of BNP and NT-proBNP the absolute levels are not 
linearly correlated. BNP is cleared from plasma mostly by binding to the natriuretic peptide 








Fig. 2. Diagrammatic representation of the cleavage of the B-type natriuretic peptide 




Fig. 3. Plot showing relation of NT-proBNP and NT-proANP to LVMI. *P < .05 vs control 
subjects. (adapted from Qi et al., 2001) 
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and passive excretion may also be responsible for some BNP clearance. In contrast, NT-
proBNP has no specific clearance receptors and is mainly cleared by renal excretion. As a 
result, NT-proBNP has a longer half-life and circulates in higher concentrations in plasma. 
NT-proBNP is less influenced by short bursts of secretion, even though both molecules are 
released in equimolar proportions. (Qi, 2001; Boomsma, 2001)  
ANP and NT-proANP are most closely associated with left atrial (LA) pressure as 
represented by pulmonary capillary wedge pressure (Qi et al., 2001) and the levels may 
result from increased LA pressure caused by LV systolic dysfunction and decompensation. 
3. Natriuretic peptide levels in other cardiac and non-cardiac states 
A number of cardiac and non-cardiac co-morbidities may influence natriuretic peptide 
levels. Cardiac examples include acute coronary syndromes, (de Lemos et al., 2001) mitral 
regurgitation, (Sutton et al., 2003) hypertrophic cardiomyopathy, (Hasegawa et al., 1993) 
advanced LV diastolic dysfunction, (Iwanaga et al., 2006) atrial fibrillation, (Iwanaga et al., 
2006) and heart failure. Non-cardiac examples include severe respiratory disease, (Jensen et 
al., 1997) renal failure, (Jensen et al., 1997) fluid overload, and obesity. In patients with 
chronic kidney disease, decreased estimated glomerular filtration rate (GFR) is associated 
with increased plasma BNP and even greater elevation in NT-proBNP concentrations. 
Higher cut-off values for those with GFR <60mL/min/1.7m2 have been suggested. 
(McCullough, 2003; Anwaruddin, 2006) 
On average, obese patients tend to have lower plasma BNP and NT-proBNP levels than 
non-obese patients. (Das, 2005; Wang, 2005; Horwich, 2006) An inverse relationship between 
body mass index (BMI) and natriuretic peptides has been observed in patients both with 
and without heart failure. The underlying mechanism remains to be elucidated. Higher 
plasma BNP values within any body mass index category are associated with worse 
outcomes, (Horwich, 2006) although lower cut-offs are needed for diagnosing heart failure 
in obese patients. 
It is unclear whether a single cut-point for the natriuretic peptides, as used for BNP in the 
diagnosis of heart failure (100 pg/mL), (Maisel et al., 2002) is appropriate for patients of all 
ages and both genders. Natriuretic peptide levels increase with aging in normal subjects and 
values are higher in women than in men with no cardiac disease after adjustment for age. 
(Wang, 2002; Gerber, 2003; Redfield, 2002) Some studies suggest BNP levels are related to 
oestrogen and/or testosterone levels, although results have been inconsistent. (Redfield, 
2002; Costello-Boerrigter, 2006; Chang, 2007) These observations suggest the use of an age- 
and sex-specific threshold in different clinical settings could improve the diagnostic 
accuracy of natriuretic peptide levels and the clinical cut-off level should be elucidated in 
further studies. The specific assay used can also affect natriuretic peptide levels and 
contribute to different “normal” values.  
4. Natriuretic peptides in aortic stenosis 
Natriuretic peptide levels increase with the severity of aortic disease. (Gerber, 2003; Weber, 
2005; Bergler-Klein, 2004; Weber, 2004) BNP and NT-proBNP levels correlate with peak-to-
peak aortic valve and mean aortic gradient, and the correlation coefficients were stronger for 
BNP than for ANP. (Qi, 2001; Poulsen, 2007) Elevated BNP is also associated with lower 
AVA, (Gerber, 2003; Lim, 2004; Qi, 2001; Weber, 2003) although the correlation is lower than 
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with other echocardiographic parameters. The plasma level of BNP also increases with 
decrease in LV systolic function. These observations suggest serial measurements of BNP 
may be useful for monitoring patients with asymptomatic AS.  
In the natural history of AS, a latent stage may exist during which LV hypertrophy 
compensates for the rise in afterload without producing a concomitant elevation of mean 
atrial pressure. As disease progresses, decompensation may occur with a reduction in the 
ratio between wall thickness and LV cavity size and a rise in atrial and pulmonary capillary 
wedge pressures.  
4.1 Natriuretic peptides and functional status of AS patients 
The transition from compensated to decompensated LV function may not be reliably 
detected by current echocardiographic measures such as ejection fraction, stroke volume, 
and transvalvular flow. In contrast, levels of natriuretic peptides correlate with the New 
York Heart Association (NYHA) symptom class and echocardiographic measures of LV 
dysfunction and therefore may be useful in indicating subtle LV pathology in asymptomatic 
patients. (Lim, 2004; Van Pelt, 2008; Weber, 2005; Gerber, 2005) Importantly, natriuretic 
peptide levels are on average higher in patients with NYHA class II symptoms than in 
patients with class I symptoms. This supports the notion that natriuretic peptide levels 
could be used to discriminate between early heart failure symptoms and normal effort 
tolerance (Figure 4). Interestingly, AVA is poorly correlated with the presence of symptoms. 
(Lim et al., 2004) 
 
 
Fig. 4. Association between BNP levels (indicated as median and quartiles) and NYHA 
functional class (trend test, p < 0.01). (adapted from Lim et al., 2004) 
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In a study by Gerber et al and colleagues, 74 patients with severe AS were sub-grouped 
according to their AVA, symptom status, and LV EF. BNP and NT-proBNP levels were 
consistently higher in symptomatic patients referred for surgery whereas asymptomatic 
patients had lower natriuretic peptide levels (Figure 5). (Gerber et al., 2003) 
 
 
Fig. 5. Association between N-BNP levels and severity of aortic stenosis. The N-BNP levels 
(median [upper quartile]) in normal control subjects and in subgroups of patients with 
aortic stenosis by aortic valve area, symptoms, and LV systolic function are shown. AVA 
indicates aortic valve area; EF, ejection fraction. (adapted from Gerber et al., 2003) 
Within each NYHA class, natriuretic peptide levels were not higher in patients with angina 
or syncope than in those without these symptoms, suggesting different pathophysiologies 
for these symptoms.  
In a separate study, Gerber et al followed 29 asymptomatic patients with AS for an average 
of eighteen months. (Gerber et al., 2005) Patients with a plasma level of NT-proBNP that 
exceeded normal limits (>50 pmol/L) at baseline were more likely to develop symptoms 
earlier and significantly more often than those whose NT-proBNP levels were within 
normal limits. The average increase in NT-proBNP per year was also greater in patients who 
developed symptoms compared with those who remained asymptomatic. AVA, peak aortic 
velocity, and the ejection fraction were less reliable predictors of symptom onset. Similar 
findings were observed by Bergler-Klein et al in a group of 43 initially asymptomatic 
patients. (Bergler-Klein et al., 2004) 
An abnormal blood pressure response to exercise is generally considered an indication for 
AVR in patients with asymptomatic AS. (Bonow et al., 2006) Exercise testing is 
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recommended to assess AS patients with equivocal symptoms. However, there is sometimes 
reluctance to undertake an exercise test, or the patient may not be able to perform the test 
due to co-morbidities. A rise in plasma BNP may reflect early systolic dysfunction which 
results in a decrease in exercise capacity. Van Pelt et al demonstrated that AS patients with 
an increase in systolic BP of ≤20 mmHg during exercise had higher plasma levels of BNP 
than patients with an increase in systolic BP >20 mmHg. (Van Pelt et al., 2008) BNP was a 
superior predictor of abnormal blood pressure response than AVA, LV EF, diastolic 
function, and LV mass index. These observations support the use of BNP for monitoring 
asymptomatic patients or patients with equivocal symptoms, as well as patients who are 
unable to exercise. Newer echocardiographic methods such as tissue Doppler or speckle 
tracking methods which detect early deterioration of LV function also correlate with BNP 
levels. (Poulsen, 2007; Van Pelt, 2007) 
4.2 Natriuretic peptides to predict outcome in asymptomatic severe AS 
Echocardiography is the primary investigation for the assessment and monitoring of 
patients with AS, and the degree of aortic valve calcification, (Rosenhek et al., 2000) aortic 
valve area, parameters of LV function and LV hypertrophy each predict outcome in this 
group of patients, (Otto et al., 1997) although the severity of AS is the most important 
predictor. (Stewart et al., 2010) However, these echocardiographic parameters have only 
modest value in predicting individual risk. BNP levels have been shown to be 
independently prognostic of cardiovascular outcomes in patients with aortic stenosis who 
are treated without surgery (Figure 6). (Nessmith, 2005; Weber, 2006) BNP level is also an 
independent predictor for cardiovascular death in asymptomatic patients. (Lim et al., 2004) 
This may be explained if BNP is a more sensitive marker of early LV dysfunction than 
symptoms.  
The risk of sudden cardiac death, (Pellikka, 2005; Rosenhek, 2000) as well as the risk of 
irreversible myocardial damage due to LV hypertrophy, (Lund et al., 2004) make risk 
stratification of patients with AS important. A comprehensive and objective approach that 
will facilitate decision making would, therefore, be of value. 
A scoring system to predict adverse outcomes has been created by Monin et al for patients 
with asymptomatic severe aortic stenosis based on risk score including gender, BNP and 
peak aortic jet velocity at baseline. (Monin et al., 2009) These variables were chosen because 
each was independently associated with midterm adverse outcome. As no single value is an 
absolute criterion to define haemodynamic severity or to predict the development of 
symptoms, a continuous score integrating valve and ventricular related parameters may be 
more appropriate in selecting patients likely to benefit from early surgery. Independent 
predictors of outcome were female sex, peak aortic-jet velocity, and BNP at baseline. 
Accordingly, the score could be calculated as follows: Score = [peak velocity 
(m/s)×2]+(natural logarithm of BNP×1.5)+1.5 (if female sex). The use of aortic valve velocity 
and BNP emphasizes the haemodynamic effects at a valve level as well as the impact on the 
ventricle. Event-free survival after 20 months was 80% for patients within the first score 
quartile compared with only 7% for the fourth quartile. Areas under the receiver operating 
characteristic curves showed excellent performance of their risk score calculation. Future 
studies will also be needed to validate this strategy before implementing it as a risk 
calculator for bedside use. 
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Fig. 6. Kaplan–Meier curves of event-free survival (freedom from cardiac death or 
rehospitalisation for decompensated heart failure (CHF)) of patients according to N-
terminal pro-B-type natriuretic peptide (NT-proBNP) values above (solid line) and below 
(dotted line) a cut-off value of 640 pg/ml. (A) All patients. (B) Only conservatively treated 
patients. (C) Only surgically treated patients. CI, confidence interval; HR, hazard ratio. 
(adapted from Weber et al., 2006) 
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4.3 Natriuretic peptides and outcomes after aortic valve replacement 
Preoperative NT-proBNP independently predicts perioperative and postoperative survival, 
necessity of intra-aortic balloon pump, postoperative symptomatic status, postoperative 
hospital stay, and postoperative LV function in patients undergoing heart surgery of various 
aetiologies. (Hutfless, 2004; Provenchere, 2006) Persistently elevated postoperative BNP 
levels are also associated with poorer outcomes and higher mortality after heart surgery. 
(Hutfless et al., 2004) 
In symptomatic severe AS patients referred for AVR, preoperative natriuretic peptides were 
correlated with postoperative NYHA symptom class, LV function, and mortality. (Bergler-
Klein, 2004; Predrazzini, 2008) Following AVR, BNP and NT-proBNP levels decrease over 
time, consistent with the expected haemodynamic improvement after valve replacement 
with relief of the LV afterload followed by reverse remodelling with gradual regression of 
LV hypertrophy. (Qi, 2002; Poulsen, 2007) The largest reduction is seen in patients with the 
largest postoperative valve area index. The postoperative decrease of NT-proBNP had also 
been demonstrated in some patients to be independently related to improvement of LV 
myocardial systolic longitudinal strain in echocardiography. (Van Pelt, 2007) However, BNP 
levels do not decrease in some patients. This may be due to persistent LV dysfunction or 
aortic prosthesis mismatch with a persistent residual LV outflow gradient from a small 
prosthetic valve orifice area. Patients who did not derive a symptomatic improvement from 
AVR were in lower NYHA class at baseline and had a tendency towards lower levels of NT-
proBNP at study entry. (Weber et al., 2005) 
5. BNP in low-flow, low-gradient aortic stenosis 
The prognostic value of BNP in the particularly challenging subset of patients who have 
low-flow and low-gradient AS has also been studied. It is critical from the perspective of 
therapeutic decisions to make the distinction between severe AS and pseudo-severe AS who 
have a high operative mortality (Monin, 2003; Connolly, 2000) and a poor prognosis. It 
remains unclear which patients would derive benefit from AVR and which could be treated 
medically. In severe AS, the LV systolic dysfunction is related to the duration and severity 
of AS. In pseudo-severe AS, LV dysfunction from other causes results in low forward flow 
and reduced valve opening which overestimates the severity of AS. Dobutamine stress 
echocardiography (DSE) is potentially useful in distinguishing the two conditions (Blais, 
2006; De Filippi, 1995) by assessing the response of valve area and gradient to a 
dobutamine-induced flow increase. Nonetheless, this differentiation remains difficult and it 
is uncertain whether DSE can reliably predict the outcome with surgery. (Monin, 2003; 
Quere, 2006) 
Bergler-Klein and colleagues reported on 69 low-flow, low-gradient patients who 
underwent inotropic challenge and related the outcome to their BNP levels (Figure 7). 
(Bergler-Klein et al., 2007) The study included 29 patients with severe AS and 40 patients 
with pseudo-severe AS. BNP levels were higher in patients with true AS when compared 
with pseudo-AS, a finding consistent with the concept that BNP is elevated in AS due to the 
effect on wall tension and ventricular stretch associated with the increased after-load in 
addition to the failing LV. Nonetheless, a significant overlap of BNP values was observed 
between groups.  
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Fig. 7. Kaplan-Meier survival curve for the entire study population according to baseline 
BNP<550 or 550 pg/mL. A BNP of >550 pg/mL was found to be associated with a poor 
outcome for both groups, with only 47% of such patients surviving for 1 year compared 
with 97% survival in patients with lower BNP values. (adapted from Bergler-Klein et al., 
2007)) 
BNP level >550 pg/mL remained the strongest independent predictor of survival when 
factors such as New York Heart Association functional class, LV EF, contractile reserve, the 
status of true or pseudo-AS, medical versus surgical therapy, and other clinical variables 
such as coronary artery disease or diabetes were considered. Therefore, BNP could 
potentially be used to improve risk stratification and management of this group of patients. 
However, BNP is non-specific with plasma levels increasing with heart failure due to many 
causes. More data will be required before BNP can be formally used for therapeutic 
recommendations.  
6. Conclusion 
Together with clinical and echocardiographic parameters, measurement of BNP may 
improve risk stratification and management of patients with AS. BNP and NT-proBNP are 
important prognostic markers and predictors of symptom-free survival in patients with 
severe AS. A patient with severe AS and a high plasma level of BNP is likely to carry a high 
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risk of adverse events, and aortic valve replacement should be considered. Measurement of 
BNP may complement clinical and echocardiographic evaluation, allow more reliable 
follow-up, and improve the optimal timing of AVR surgery by early identification of the 
transition from compensated to decompensated LV function. Serially rising levels could also 
be helpful in identifying patients with LV dysfunction, but current evidence for such use is 
limited. Clinical judgment will be needed to interpret the significance of a BNP 
measurement in patients with AS. 
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